Under-reporting of harm in clinical trials

The Lancet Oncology

Volumn 17, Issue 5, 2016, Pages e209-e219

  Seruga, Bostjan ^a   Templeton, Arnoud J ^b   Badillo, Francisco Emilio Vera ^c   Ocana, Alberto ^d   Amir, Eitan ^e   Tannock, Ian F ^e  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c QUEEN S UNIVERSITY   (Canada)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CETUXIMAB; DOCETAXEL; TEMSIROLIMUS;

ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CARDIOPULMONARY ARREST; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL STATUS ASSESSMENT; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LICENSING; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; METASTATIC COLORECTAL CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE C30; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHICS; METHODOLOGY; NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; RISK ASSESSMENT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEOPLASMS; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 84964636326     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)00152-2     Document Type: Review

References (74)

1. Basch E The missing voice of patients in drug-safety reporting. N Engl J Med 2010, 362:865-869.
2. National Institutes of Health. National Cancer Institute: Common Terminology Criteria for reporting of Adverse Events (CTCAE). Version 4 US Department of Health and Human Services, (accessed April 4, 2016). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
3. Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007, 25:5121-5127.
4. Edgerly M, Fojo T Is there room for improvement in adverse event reporting in the era of targeted therapies?. J Natl Cancer Inst 2008, 100:240-242.
5. Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res 2012, 21:1159-1164.
6. Di Maio M, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 2015, 33:910-915.
7. Novello S, Capelletto E, Cortinovis D, et al. Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice. Transl Lung Cancer Res 2014, 3:173-180.
8. Quinten C, Maringwa J, Gotay CC, et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 2011, 103:1851-1858.
9. Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 2009, 101:1624-1632.
10. Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care 2008, 14:530-539.
11. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 2006, 7:903-909.
12. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004, 22:3485-3490.
13. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria For Adverse Events (PRO-CTCAE). J Natl Cancer Inst 2014, 106:dju244.
14. Weingart SN, Simchowitz B, Shiman L, et al. Clinicians' assessments of electronic medication safety alerts in ambulatory care. Arch Intern Med 2009, 169:1627-1632.
15. Basch E, Bennett A, Pietanza MC Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 2011, 103:1808-1810.
16. Alberti P, Rossi E, Cornblath DR, et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 2014, 25:257-264.
17. Brundage M, Bass B, Davidson J, et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res 2011, 20:653-664.
18. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015, 373:1803-1813.
19. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015, 373:1814-1823.
20. Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013, 14:760-768.
21. Dwan K, Altman DG, Clarke M, et al. Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials. PLoS Med 2014, 11:e1001666.
22. Williamson PR, Gamble C, Altman DG, Hutton JL Outcome selection bias in meta-analysis. Stat Methods Med Res 2005, 14:515-524.
23. Ioannidis JP Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 2009, 169:1737-1739.
24. Ioannidis JP, Evans SJ, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004, 141:781-788.
25. Sivendran S, Latif A, McBride RB, et al. Adverse event reporting in cancer clinical trial publications. J Clin Oncol 2014, 32:83-89.
26. Péron J, Maillet D, Gan HK, Chen EX, You B Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. J Clin Oncol 2013, 31:3957-3963.
27. Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. Ann Oncol 2015, 27:192-198.
28. Mhaskar RS, Reljic T, Wao H, Kumar A, Miladinovic B, Djulbegovic B Treatment-related harms: what was planned and what was reported? National Cancer Institute's Co-operative group phase III randomized controlled trials: a systematic review. J Clin Epidemiol 2014, 67:354-356.
29. Vera-Badillo FE, Shapiro R, Ocana A, Amir E, Tannock IF Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol 2013, 24:1238-1244.
30. Pitrou I, Boutron I, Ahmad N, Ravaud P Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009, 169:1756-1761.
31. Scharf O, Colevas AD Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 2006, 24:3933-3938.
32. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004, 291:2457-2465.
33. Booth CM, Le Maître A, Ding K, et al. Presentation of nonfinal results of randomized controlled trials at major oncology meetings. J Clin Oncol 2009, 27:3938-3944.
34. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005, 294:2203-2209.
35. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010, 303:1180-1187.
36. Elimova E, Seruga B, Jiang H, Tannock IF Comparison of results between the first and updated reports of phase III clinical trials (RCTs). J Clin Oncol 2014, 32. abstr 6520.
37. Rothwell PM External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 2005, 365:82-93.
38. Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice. J Oncol Pract 2015, 11:491-497.
39. Treweek S, Dryden R, McCowan C, Harrow A, Thompson AM Do participants in adjuvant breast cancer trials reflect the breast cancer patient population?. Eur J Cancer 2015, 51:907-914.
40. Heng DY, Choueiri TK, Rini BI, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 2014, 25:149-154.
41. Templeton AJ, Vera-Badillo FE, Wang L, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013, 24:2972-3027.
42. Mol L, Koopman M, van Gils CW, Ottevanger PB, Punt CJ Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol 2013, 52:950-955.
43. Sorbye H, Pfeiffer P, Cavalli-Björkman N, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009, 115:4679-4687.
44. AlHashem HY, Al-Mubarak M, Vera-Badillo FE, et al. Impact of geographic region on benefit of approved anticancer drugs evaluated in international phase III clinical trials. Clin Oncol (R Coll Radiol) 2015, published online Nov 2. 10.1016/j.clon.2015.09.010.
45. Bracarda S, Gernone A, Gasparro D, et al. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol 2014, 10:975-983.
46. Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014, 12:116.
47. Berlin JA, Glasser SC, Ellenberg SS, et al. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health 2008, 98:1366-1371.
48. Crossing the quality chasm: a new health system for the 21st century 2001, Institute of Medicine CoQoHCiA, National Academy Press, Washington, DC.
49. Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008, 9:1166-1172.
50. Seruga B, Sterling L, Wang L, Tannock IF Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 2011, 29:174-185.
51. FDA Approved Drug Products FDA, (accessed Dec 13, 2015). http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125084s046LBL.pdf.
52. Psaty BM, Kronmal RA Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA 2008, 299:1813-1817.
53. Lurie P, Wolfe SM Misleading data analyses in salmeterol (SMART) study. Lancet 2005, 366:1261-1262.
54. Habibi R, Lexchin J Quality and quantity of information in summary basis of decision documents issued by health Canada. PLoS One 2014, 9:e92038.
55. Hazell L, Shakir SA Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006, 29:385-396.
56. Carpenter D, Zucker EJ, Avorn J Drug-review deadlines and safety problems. N Engl J Med 2008, 358:1354-1361.
57. Hazell L, Cornelius V, Hannaford P, et al. How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme. Drug Saf 2013, 36:199-206.
58. Margraff F, Bertram D Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf 2014, 37:409-419.
59. Fu AZ, Graves KD, Jensen RE, Marshall JL, Formoso M, Potosky AL Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment. J Cancer Res Clin Oncol 2015, 142:699-706.
60. Pignatti F, Jonsson B, Blumenthal G, Justice R Assessment of benefits and risks in development of targeted therapies for cancer-the view of regulatory authorities. Mol Oncol 2015, 9:1034-1041.
61. Lexchin J Why are there deadly drugs?. BMC Med 2015, 13:27.
62. Shih YC, Halpern MT Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?. CA Cancer J Clin 2008, 58:231-244.
63. Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 2015, 1:1051-1059.
64. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 2015, published online Dec 7. 10.1200/JCO.2015.63.0830.
65. Morgans AK, van Bommel AC, Stowell C, et al. Development of a standardized set of patient-centered outcomes for advanced prostate cancer: an international effort for a unified approach. Eur Urol 2015, 68:891-898.
66. Basch E Systematic collection of patient-reported adverse drug reactions: a path to patient-centred pharmacovigilance. Drug Saf 2013, 36:277-278.
67. Ocana A, Ethier JL, Díez-González L, et al. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015, 637:39538-39549.
68. Amir E, Seruga B, Martinez-Lopez J, et al. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol 2011, 29:2543-2549.
69. Calvert M, Blazeby J, Revicki D, Moher D, Brundage M Reporting quality of life in clinical trials: a CONSORT extension. Lancet 2011, 378:1684-1685.
70. Booth CM, Tannock IF Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 2014, 110:551-555.
71. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543-551.
72. Booth CM, Shepherd FA, Peng Y, et al. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. J Clin Oncol 2010, 28:3472-3478.
73. Fosså SD, Gilbert E, Dores GM, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007, 99:533-544.
74. Ma P, Marinovic I, Karaca-Mandic P Drug manufacturers' delayed disclosure of serious and unexpected adverse events to the US Food and Drug Administration. JAMA Intern Med 2015, 175:1565-1566.